Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 07, 2021

SELL
$20.22 - $26.73 $218,901 - $289,378
-10,826 Closed
0 $0
Q4 2020

Feb 08, 2021

SELL
$23.16 - $28.08 $128,144 - $155,366
-5,533 Reduced 33.82%
10,826 $264,000
Q3 2020

Nov 04, 2020

BUY
$24.34 - $38.82 $72,022 - $114,868
2,959 Added 22.08%
16,359 $420,000
Q2 2020

Aug 12, 2020

BUY
$19.93 - $31.2 $267,062 - $418,080
13,400 New
13,400 $267,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $429M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Hc Advisors, LLC Portfolio

Follow Hc Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hc Advisors, LLC with notifications on news.